Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (4892)	11/26/1997 9:28:00 AM
From: Webhead	Read Replies (3) \| Respond to of 17367

Idec just got FDA approval for their anti-CD20 monoclonal! Just a reminder that XOMA gets royalties on this. From the PR it appears that royalties will actually come from Genentech (GNE and IDPH are cross licensed if I remember correctly). In the Idec thread, it was reported that some analyst's most recent market projection for this antibody in its uncoupled and radioactive forms is ~$500 million a year. So given even modest royalties this could mean some $10 million or so a year to XOMA. Ed ------ www1.newsalert.com

To: Robert K. who wrote (4892)	11/26/1997 2:08:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Short interest for month ended 14 Nov was 739,787 against prior mos 605,955. A 22% increase with average shrs traded of 407,640 per day. With trading slowing down it will take more days to cover. Nothing against shorts. Anyone has perfect right to sell anything short. Just think these sales made it a bit harder for xoma to go up, and my standard comment from a long time ago is that short sellers have already sold and are all potential buyers. Even if their hopes are realized and they buy back at a lower price they will provide support to the price when they do so. Whatever negative impact the sales had on the price of Xoma that has already occured.